利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

27 条记录 (耗时 0.023 秒)

    Universal introducer
    1.
    发明申请
    Universal introducer 审中-公开
    通用导引器

    公开(公告)号：US20060254603A1

    公开(公告)日：2006-11-16

    申请号：US11491763

    申请日：2006-07-24

    申请人： Stuart Edwards ,  Ronald Lax ,  Theodore Parker ,  Thomas Wehman ,  Theodore Kucklick

    发明人： Stuart Edwards ,  Ronald Lax ,  Theodore Parker ,  Thomas Wehman ,  Theodore Kucklick

    IPC分类号： A61B18/18

    CPC分类号： A61B17/00491 ,  A61B17/0057 ,  A61B17/3415 ,  A61B18/14 ,  A61B18/1482 ,  A61B18/1487 ,  A61B2017/00084 ,  A61B2017/00495 ,  A61B2017/005 ,  A61B2017/00637 ,  A61B2017/0065 ,  A61B2017/00672 ,  A61B2017/3441 ,  A61B2017/3492 ,  A61B2018/0063 ,  A61B2090/064 ,  A61M25/0662

    摘要： A device for introducing a catheter into a vessel through a puncture in a vessel and for sealing the puncture. The device includes an elongated body having a proximal end and a distal end sized to be positioned within a tissue site which includes the puncture. The elongated body includes a utility lumen sized to allow a catheter to be delivered through the utility lumen. The utility lumen is positioned within the elongated body so positioning the elongated body within the tissue site allows a catheter delivered through the utility lumen to enter the vessel. The elongated body also includes a closure lumen having an entrance port. A closure composition can be delivered through the entrance port into the closure lumen. The closure lumen also includes an exit port adjacent the distal end of the elongated body. The closure composition delivered into the closure lumen can be delivered through the exit port to the tissue site adjacent the puncture.

    摘要翻译： 一种用于通过穿孔在容器中将导管引入容器并用于密封穿刺的装置。 该装置包括细长体，其具有近端和远端，其尺寸设置成包括穿刺的组织部位内。 细长主体包括大小适于允许导管通过效用管腔输送的应用腔。 实用管腔定位在细长体内，从而将细长体定位在组织部位内，允许通过效用腔输送的导管进入血管。 细长体还包括具有入口的封闭腔。 封闭组合物可通过入口端口输送到封闭腔。 闭合腔还包括邻近细长体的远端的出口。 输送到闭合腔内的封闭组合物可以通过出口传送到穿刺附近的组织部位。

    Methods of delivering anti-restenotic agents from a stent
    4.
    发明申请
    Methods of delivering anti-restenotic agents from a stent 审中-公开
    从支架输送抗再狭窄剂的方法

    公开(公告)号：US20060178734A1

    公开(公告)日：2006-08-10

    申请号：US11325223

    申请日：2006-01-04

    申请人： Theodore Parker ,  John Shanley ,  Brett Trauthen ,  Frank Litvack ,  Stephen Diaz

    发明人： Theodore Parker ,  John Shanley ,  Brett Trauthen ,  Frank Litvack ,  Stephen Diaz

    IPC分类号： A61F2/06

    CPC分类号： A61L31/16 ,  A61F2/91 ,  A61F2210/0004 ,  A61F2230/0054 ,  A61F2250/0068 ,  A61L2300/416 ,  A61L2300/602

    摘要： A method for decreasing the level of restenosis following a stent placement medical intervention involves the continuous administration of a dose of an anti-restenotic agent, such as paclitaxel, from the stent to vascular tissue in need of treatment in a controlled, extended, and substantially linear drug release profile. The method of substantially linear extended release increases the therapeutic effectiveness of administration of a given dosage. In one example, a method of reducing restenosis includes delivering paclitaxel from a stent to an artery at a minimum release rate of 1 percent of the total dosage of paclitaxel on the stent per day throughout an entire administration period from the time of implantation of the stent until the time that substantially all the paclitaxel is released from the stent.

    摘要翻译： 用于降低支架置入医疗干预后再狭窄水平的方法包括将需要治疗的受支配物，延长和基本上的支架的支架到血管组织的持续施用一定剂量的抗再狭窄剂如紫杉醇 线性药物释放曲线。 基本线性延长释放的方法增加给药剂量的给药的治疗有效性。 在一个实例中，减少再狭窄的方法包括将紫杉醇从支架输送到动脉，在从支架植入开始的整个施用期间，每天在支架上以最大释放速率将紫杉醇的总剂量的1％ 直到基本上所有的紫杉醇从支架释放出来。

    Methods and systems for delivering immunosuppressant and anti-inflammatory agents from a stent
    7.
    发明申请
    Methods and systems for delivering immunosuppressant and anti-inflammatory agents from a stent 审中-公开
    从支架输送免疫抑制剂和抗炎剂的方法和系统

    公开(公告)号：US20060204546A1

    公开(公告)日：2006-09-14

    申请号：US11375454

    申请日：2006-03-14

    申请人： Thai Nguyen ,  John Shanley ,  Frank Litvack ,  Theodore Parker

    发明人： Thai Nguyen ,  John Shanley ,  Frank Litvack ,  Theodore Parker

    IPC分类号： A61F2/06

    CPC分类号： A61F2/915 ,  A61F2/91 ,  A61F2002/91541 ,  A61F2250/0068 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/416

    摘要： A method for decreasing the level of restenosis following a stent placement medical intervention involves the continuous administration of a dose of an immunosuppressant or anti-inflammatory agent from reservoirs in a stent to vascular tissue in need of treatment in a controlled, two phase drug release profile. It is envisioned that the vascular tissue in need of treatment is arterial tissue, specifically coronary arterial tissue. The agent or drug can be the calcineurin inhibitor Pimecrolimus. The drug can be held within reservoirs in the stent in a drug delivery matrix comprised of the drug and a bioresorbable polymeric material and optionally additives to regulate the drug release.

    摘要翻译： 用于降低支架置入医疗干预后再狭窄水平的方法包括将需要在受控的两相药物释放曲线中进行治疗的支架中的血管中的一个剂量的免疫抑制剂或抗炎药剂的剂量连续施用于血管组织 。 可以想象，需要治疗的血管组织是动脉组织，特别是冠状动脉组织。 该药物或药物可以是钙调神经磷酸酶抑制剂Pimecrolimus。 该药物可以在由药物和生物可再吸收的聚合物材料和任选的调节药物释放的添加剂的药物递送基质中的支架内的储存器中保持。

    Expandable medical device with beneficial agent matrix formed by a multi solvent system
    8.
    发明申请
    Expandable medical device with beneficial agent matrix formed by a multi solvent system 审中-公开
    具有由多溶剂体系形成的有益剂基质的可扩展医疗器械

    公开(公告)号：US20050100577A1

    公开(公告)日：2005-05-12

    申请号：US10830566

    申请日：2004-04-22

    申请人： Theodore Parker ,  John Shanley ,  Micheline Markey

    发明人： Theodore Parker ,  John Shanley ,  Micheline Markey

    IPC分类号： A61F2/00 ,  A61F2/06 ,  A61F2/90 ,  A61L31/10 ,  A61L31/14 ,  A61L31/16 ,  A61K38/28 ,  A61K9/22 ,  A61K31/445 ,  A61K31/7076

    CPC分类号： A61L31/148 ,  A61F2/91 ,  A61F2/915 ,  A61F2002/91541 ,  A61F2210/0076 ,  A61F2250/0068 ,  A61L31/10 ,  A61L31/14 ,  A61L31/146 ,  A61L31/16 ,  A61L2300/416 ,  A61L2300/43 ,  A61L2300/606 ,  A61L2300/61 ,  A61L2420/02 ,  A61L2420/08

    摘要： A multi solvent drug delivery matrix formation method is used to place layers into a reservoir in a stent in a stepwise manner to achieve extended delivery of water soluble, sensitive, or difficult to deliver drugs. The multi solvent matrix formation method allows the formation of a drug reservoir with a layered morphology in which the mixing between layers is limited to allow the different layers to perform different functions in controlling drug delivery. A stent having a drug delivery matrix includes a first beneficial agent layer affixed to the stent by depositing a first solution of a first polymer and a first solvent, and a second beneficial agent layer affixed to the first beneficial agent layer by depositing a second solution of a second polymer and a second solvent. The second solvent is selected so that the first polymer is substantially insoluble in the second solvent to prevent degradation of the first polymer during deposition of the second polymer. A therapeutic agent is provided in the first beneficial agent layer or the second beneficial agent layer to form a drug delivery matrix.

    摘要翻译： 使用多溶剂药物递送基质形成方法以逐步方式将层放置在支架中的储存器中以实现水溶性，敏感或难以递送的药物的延长递送。 多溶剂基质形成方法允许形成具有分层形态的药物储存器，其中层之间的混合被限制以允许不同的层在控制药物递送中执行不同的功能。 具有药物递送基质的支架包括通过沉积第一聚合物和第一溶剂的第一溶液而固定到支架上的第一有益剂层和通过沉积第一有益剂层的第二溶液 第二聚合物和第二溶剂。 选择第二溶剂使得第一聚合物基本上不溶于第二溶剂以防止第二聚合物沉积期间第一聚合物的降解。 在第一有益剂层或第二有益剂层中提供治疗剂以形成药物递送基质。

    ASSOCIATIVE ONLINE ADVERTISEMENT
    9.
    发明申请
    ASSOCIATIVE ONLINE ADVERTISEMENT 审中-公开
    相关在线广告

    公开(公告)号：US20110282743A1

    公开(公告)日：2011-11-17

    申请号：US12781665

    申请日：2010-05-17

    申请人： Roger Gerdes ,  Theodore Parker

    发明人： Roger Gerdes ,  Theodore Parker

    IPC分类号： G06Q30/00 ,  G06Q99/00

    CPC分类号： G06Q30/02 ,  G06Q30/0257

    摘要： Embodiments of methods and apparatuses for associative online advertisement are disclosed. In various embodiments, an online advertisement of a product or service provider may be selectively associated with a member of an online social network, under the selection control of the member. In various embodiments, the association enables at least another member of the online social network to select the online advertisement from a social media associated with the member to be likewise associated with the online advertisement, or purchase for the member, a product or service of the associated product or service provider. Other embodiments may be disclosed and/or claimed.

    摘要翻译： 公开了关联在线广告的方法和装置的实施例。 在各种实施例中，在成员的选择控制下，产品或服务提供商的在线广告可以选择性地与在线社交网络的成员相关联。 在各种实施例中，该关联使得在线社交网络的至少另一个成员能够从与该成员相关联的社交媒体中选择同样与在线广告相关联的在线广告，或者为该成员购买该产品或服务 相关产品或服务提供商。 可以公开和/或要求保护其他实施例。

    System and method for local delivery of antithrombotics
    10.
    发明申请
    System and method for local delivery of antithrombotics 审中-公开
    用于局部递送抗血栓药物的系统和方法

    公开(公告)号：US20070112414A1

    公开(公告)日：2007-05-17

    申请号：US11516054

    申请日：2006-09-05

    申请人： Theodore Parker ,  Frank Litvack ,  Micheline Lisa Markey

    发明人： Theodore Parker ,  Frank Litvack ,  Micheline Lisa Markey

    IPC分类号： A61F2/06

    CPC分类号： A61L31/16 ,  A61L31/146 ,  A61L2300/21 ,  A61L2300/402 ,  A61L2300/416 ,  A61L2300/42

    摘要： Dipyridamole is an antithrombotic agent which also promotes the growth of endothelial cells. An endothelial cell lining within a stent is necessary for complete healing on the interior of the stent. A dual drug dipyridamole stent includes a first drug formulation of dipyridamole and polymer arranged in a first set of holes in the stent for primarily luminal delivery and a second drug formulation of an antirestenotic agent and polymer arranged in a second set of holes in the stent for primarily mural delivery. The delivery of dipyridamole luminally into the blood stream can involve a two phase release with the first phase being a burst to prevent initial clotting or thrombus formation followed by a second phase with a much slower and more sustained release to reduce thrombogenicity and promote the growth of the endothelial cell lining.

    摘要翻译： 双嘧达莫是一种还促进内皮细胞生长的抗血栓形成剂。 支架内部的内皮细胞衬里对于在支架内部完全愈合是必需的。 双药双嘧达莫支架包括双嘧达莫的第一药物制剂和布置在支架中的第一组孔中的聚合物，用于主要的腔内递送，以及布置在支架中的第二组孔中的抗再狭窄剂和聚合物的第二药物制剂， 主要是壁画交付。 将双嘧达莫光发射到血液中可涉及两相释放，第一阶段是爆发，以防止初始凝血或血栓形成，随后是具有更慢和更持续释放的第二相以降低血栓形成并促进生长 内皮细胞内衬。